Literature DB >> 21214343

Validity of the International HIV Dementia Scale in South Africa.

John A Joska1, Jennifer Westgarth-Taylor, Jacqueline Hoare, Kevin G F Thomas, Robert Paul, Landon Myer, Dan J Stein.   

Abstract

HIV-associated neurocognitive disorders (HAND) remain prevalent, especially in regions like South Africa where HIV prevalence is high but access to antiretroviral treatment (ART) is limited. The incidence of HIV dementia (HAD) has been halved with the use of ART, but the prevalence remains high. Appropriate brief screening tools to screen for HAD are needed in order to facilitate treatment initiation. The validity of the International HIV Dementia Scale has not been established in a region where infection with HIV clade C is predominant. The International HIV Dementia Scale (IHDS) was administered together with a detailed neuropsychological test battery to 96 HIV-positive individuals who had not received ART and who were attending primary care HIV clinics. The validity of the IHDS was established using a receiver operating characteristic (ROC) analysis. HIV-positive individuals displayed greater impairment when compared to HIV-negative controls on the IHDS and a range of neuropsychological tests. Neuropsychological tests discriminated well across HAND categories for HIV-positive individuals. In ROC analysis, the IHDS showed an area under the curve of 0.64, with a sensitivity of 45% and specificity of 79% at a cutoff score of 10. Individuals with HAD, who screened negative on the IHDS, performed poorly on some tests of executive function. These data suggest that the IHDS may have limitations as a tool to screen for HAD in South Africans infected with HIV. Variable performance in neuropsychological testing may account for false negative screens. The inclusion of brief tests of executive function in a screening battery should be considered.

Entities:  

Mesh:

Year:  2011        PMID: 21214343     DOI: 10.1089/apc.2010.0292

Source DB:  PubMed          Journal:  AIDS Patient Care STDS        ISSN: 1087-2914            Impact factor:   5.078


  35 in total

1.  Cognitive disorders in HIV-infected and AIDS patients in Guangxi, China.

Authors:  Tingting Zhao; Bo Wei; Jianxiong Long; Xianyan Tang; Mengxiao Zhou; Chao Dang
Journal:  J Neurovirol       Date:  2014-11-01       Impact factor: 2.643

2.  A Comparison of Five Brief Screening Tools for HIV-Associated Neurocognitive Disorders in the USA and South Africa.

Authors:  J A Joska; J Witten; K G Thomas; C Robertson; M Casson-Crook; H Roosa; J Creighton; J Lyons; J McArthur; N C Sacktor
Journal:  AIDS Behav       Date:  2016-08

Review 3.  Effect of HIV clade differences on the onset and severity of HIV-associated neurocognitive disorders.

Authors:  William Tyor; Cari Fritz-French; Avindra Nath
Journal:  J Neurovirol       Date:  2013-10-16       Impact factor: 2.643

4.  Identifying risk factors for HIV-associated neurocognitive disorders using the international HIV dementia scale.

Authors:  Sara Cross; Nur Önen; Amber Gase; Edgar Turner Overton; Beau M Ances
Journal:  J Neuroimmune Pharmacol       Date:  2013-10-10       Impact factor: 4.147

Review 5.  Epidemiology of neurodegenerative diseases in sub-Saharan Africa: a systematic review.

Authors:  Alain Lekoubou; Justin B Echouffo-Tcheugui; Andre P Kengne
Journal:  BMC Public Health       Date:  2014-06-26       Impact factor: 3.295

6.  Improving Detection of HIV-Associated Cognitive Impairment: Comparison of the International HIV Dementia Scale and a Brief Screening Battery.

Authors:  Sérgio Monteiro de Almeida; Rujvi Kamat; Mariana Cherner; Anya Umlauf; Clea E Ribeiro; Ana Paula de Pereira; Donald Franklin; Robert K Heaton; Ronald J Ellis
Journal:  J Acquir Immune Defic Syndr       Date:  2017-03-01       Impact factor: 3.731

7.  Trail Making Test A improves performance characteristics of the International HIV Dementia Scale to identify symptomatic HAND.

Authors:  Thep Chalermchai; Victor Valcour; Pasiri Sithinamsuwan; Suteeraporn Pinyakorn; David Clifford; Robert H Paul; Somporn Tipsuk; James L K Fletcher; Victor Degruttola; Silvia Ratto-Kim; Nicholas Hutchings; Cecilia Shikuma; Jintanat Ananworanich
Journal:  J Neurovirol       Date:  2013-03-13       Impact factor: 2.643

8.  Longitudinal neuropsychological test performance among HIV seropositive individuals in Uganda.

Authors:  Ned Sacktor; Noeline Nakasujja; Ozioma Okonkwo; Richard L Skolasky; Kevin Robertson; Seggane Musisi; Elly Katabira
Journal:  J Neurovirol       Date:  2013-01-12       Impact factor: 2.643

9.  Exploring the utility of the Montreal Cognitive Assessment to detect HIV-associated neurocognitive disorder: the challenge and need for culturally valid screening tests in South Africa.

Authors:  Reuben N Robbins; John A Joska; Kevin G F Thomas; Dan J Stein; Teboho Linda; Claude A Mellins; Robert H Remien
Journal:  Clin Neuropsychol       Date:  2013-01-21       Impact factor: 3.535

10.  The Alzheimer's disease-8 and Montreal Cognitive Assessment as screening tools for neurocognitive impairment in HIV-infected persons.

Authors:  Edgar Turner Overton; Tej D Azad; Neva Parker; Debra Demarco Shaw; Judy Frain; Teresa Spitz; Elizabeth Westerhaus; Robert Paul; David B Clifford; Beau M Ances
Journal:  J Neurovirol       Date:  2013-01-24       Impact factor: 2.643

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.